| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 12, 2012The site is located in Vienna, Austria. The prospective, open-label study will enroll adolescents and adults (12 – 65 years) who have hemophilia B.
12 Jan 2012 CSL Behring has announced that the first site has been initiated in its global phase II/III, multi-center study to evaluate the safety, efficacy and pharmacokinetics of recombinant...
-
Jan 3, 2012CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder.
03 Jan 2012 CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert®, C1 Esterase Inhibitor (Human), a...
-
Dec 2, 2011CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program.
02 Dec 2011 CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD)...
-
Nov 5, 2011New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type II hereditary angioedema (HAE), a rare and serious genetic disorder. Study results show that the outcomes of treatment with C1-INH during acute HAE attacks in children and adolescents are comparable to the outcomes observed in adults.
05 Nov 2011 New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type...
-
Nov 5, 2011C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to final data presented today at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.
05 Nov 2011 C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients...
-
Nov 4, 2011National Jewish Health (NJH) announced that Jordan Abbott, M.D., is the recipient of the CSL Behring – National Jewish Health Fellowship in Immunology for 2011
04 Nov 2011 National Jewish Health (NJH) announced that Jordan Abbott, M.D., is the recipient of the CSL Behring – National Jewish Health Fellowship in Immunology for 2011. Funded by an...
-
Oct 6, 2011CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27 countries, has been named Life Sciences Company of the Year by Philadelphia Business Journal and Pennsylvania Bio.
06 Oct 2011 2FRenderLink&_cid_=1255926292354&_c_=Web_Link_C">CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27...
-
Sep 29, 2011Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and cities from where they hail, places like San Antonio, Pittsburgh, Des Moines and New York..
29 Sep 2011 Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and...
-
Sep 14, 2011Every year thousands of people in the United States who suffer with rare and serious disorders such as hemophilia, hereditary angioedema, von Willebrand disease, primary immune deficiencies and inherited respiratory disease receive lifesaving therapies derived from human plasma. These conditions affect people of all ages from children to the elderly, and from all ethnic, racial and socioeconomic backgrounds.
14 Sep 2011 Every year thousands of people in the United States who suffer with rare and serious disorders such as hemophilia, hereditary angioedema, von Willebrand disease, primary immune...
-
Sep 6, 2011To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership Awards. Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.
06 Sep 2011 To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it is seeking proposals for the next round of Interlaken Leadership...
-
Aug 25, 2011CSL Behring today announced that European health authorities have approved self-administration of Berinert, a C1-esterase inhibitor (C1-INH) concentrate indicated in Europe for the treatment of acute attacks of hereditary angioedema (HAE), a rare, serious, and sometimes life-threatening genetic disorder.
25 Aug 2011 CSL Behring today announced that European health authorities have approved self-administration of Berinert®, a C1-esterase inhibitor (C1-INH) concentrate indicated in Europe for the...
-
Jul 18, 2011The donation supports WFH’s progress in improving the diagnosis and treatment of bleeding disorders in developing countries through its Global Alliance for Progress (GAP) program.
18 Jul 2011 CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation...
-
Jun 22, 2011A chronic or rare illness can harm more than a person’s health, it can also affect the strongest of relationships.
22 Jun 2011 A chronic or rare illness can harm more than a person’s health, it can also affect the strongest of relationships. Because the ill partner isn’t feeling well, he or she may be...
-
Jun 7, 2011While millions of women are experiencing symptoms that could indicate a serious bleeding disorder, nearly half of them are not discussing those symptoms with their healthcare provider, according to new survey findings.
07 Jun 2011 While millions of women are experiencing symptoms that could indicate a serious bleeding disorder, nearly half of them are not discussing those symptoms with their healthcare provider,...
-
May 31, 2011CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.
31 May 2011 CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation...
-
May 20, 2011
Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at...
-
May 17, 2011The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases."
17 May 2011 CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX:CSL), is a recipient of the National...
-
May 2, 2011CSL Behring today honored the achievements of six scientists with the inaugural 2011 Interlaken Leadership Awards for advancing medical research and knowledge about the potential role of immunoglobulin therapy for the treatment of neurological disorders. The total value of the six awards is estimated to be more than $1.2 million.
02 May 2011 CSL Behring today honored the achievements of six scientists with the inaugural 2011 Interlaken Leadership Awards for advancing medical research and knowledge about the potential role...
-
Apr 21, 2011CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra® (Human Normal Immunoglobulin), 20 percent solution for subcutaneous injection, for treating patients diagnosed with primary immunodeficiency (PI) as well as secondary immunodeficiencies. This authorization is valid for all 29 European/European Economic Area member states.
21 Apr 2011 CSL Behring announced today that the European Commission has granted marketing authorization for Hizentra® (Human Normal Immunoglobulin), 20 percent solution for subcutaneous...
-
Apr 20, 2011Thought leaders from the medical, scientific and patient advocacy communities gathered in New York and London for CSL Behring's Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies.
20 Apr 2011 in New York and London for CSL Behring's Key Issues Dialogue–Immunoglobulin to examine challenges facing patients with primary immunodeficiencies. They found common ground between...
-
Apr 19, 2011CSL Behring’s capacity to produce Hizentra, a key product in its global immunoglobulin portfolio, has more than doubled following U.S. Food and Drug Administration (FDA) approval of the company’s high tech production facility in Bern, Switzerland, where Hizentra is produced.
19 Apr 2011 CSL Behring's capacity to produce Hizentra® a key product in its global immunoglobulin portfolio, has more than doubled following U.S. Food and Drug Administration (FDA) approval of...
-
Apr 19, 2011For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can pass illnesses back and forth. The Centers for Disease Control and Prevention estimates that children have about two to nine illnesses per year, nearly double the number of colds adolescents and adults experience during the same timeframe.
19 Apr 2011 For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can...
-
Apr 15, 2011CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring Prof. Heimburger Award 2011. The announcement coincides with World Hemophilia Day and reflects this year’s theme to "Be Inspired, Get Involved in Treatment for All.
15 Apr 2011 CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring – Prof. Heimburger...
-
Mar 21, 2011Data presented by CSL Behring today suggest that treatment with higher dose Hizentra (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI). These data, presented at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting, derived from two recent trials of Hizentra, one performed in the United States and one in the European Union, and aimed to show the relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes.
21 Mar 2011 Data presented by CSL Behring today suggest that treatment with higher dose Hizentra® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients...
-
Mar 19, 2011CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision.
19 Mar 2011 CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC)...
-
Mar 2, 2011These awards honor accountable companies for openly sharing high quality information about therapies.
02 Mar 2011 CSL Behring was recognized in the 2010 Prescrire Information Awards. These awards honor accountable companies for openly sharing high quality information about therapies. Results were...
-
Feb 28, 2011CSL Behring announces a special edition of its Key Issues Dialogue series released in conjunction with Rare Disease Day 2011, an international event to raise awareness of rare diseases and their impact on people’s lives. The Dialogue spanned two continents and provided a platform for sharing and exploring important information and ideas for patients, caregivers and healthcare providers.
28 Feb 2011 CSL Behring announces a special edition of its Key Issues Dialogue series released in conjunction with Rare Disease Day 2011, an international event to raise awareness of rare diseases...
-
Feb 24, 2011CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, from 24 months to 30 months.
24 Feb 2011 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®,...
-
Feb 18, 2011CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin- P, is the first and only FXIII concentrate approved in the U.S.
18 Feb 2011 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine...
-
Jan 20, 2011CSL Behring has awarded advocacy grants totaling almost $100,000 to six patient organizations through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations committed to helping people who use plasma-derived or recombinant therapies to manage rare and serious diseases.
20 Jan 2011 CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $100,000 to six patient...
-
Dec 1, 2010CSL Behring announced today the availability of the next generation HeliTrax System as part of a specially designed software platform for Apple’s iPhone, iPod touch, or iPad devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring’s recombinant factor VIII (rFVIII).
01 Dec 2010 CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple’s iPhone®, iPod touch®, or iPad™...
-
Nov 17, 2010Huffing and puffing as he carried his luggage through airports at the age of 40, businessman Mike Wummer began to question the chronic shortness of breath he was experiencing at such a young age. Whether playing basketball or trumpet, skiing or glassblowing with his two sons, the active father would frequently have trouble breathing, forcing him to visit the emergency room.
17 Nov 2010 Huffing and puffing as he carried his luggage through airports at the age of 40, businessman Mike Wummer began to question the chronic shortness of breath he was experiencing at such a...
-
Oct 29, 2010To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards program will provide monetary grants to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurologic disorders.
29 Oct 2010 To demonstrate its continued commitment to innovative immunoglobulin (Ig) research, CSL Behring announced today it has created the Interlaken Leadership Awards. This global awards...
-
Oct 27, 2010The FDA and EMA's most recently formed discussion group addresses blood-related drug products, and pharma companies involved in the space said they hope the agencies can agree on study designs. The result could be the avoidance of unnecessary testing replication or unnecessary diverse testing methodologies, sources said.
27 Oct 2010 The FDA and EMA's most recently formed discussion group addresses blood-related drug products, and pharma companies involved in the space said they hope the agencies can agree on study...
-
Oct 18, 2010Imagine living in a world where even common germs can trigger extreme illness that won’t go away. This is the reality for nearly 10 million children and adults living with primary immunodeficiency (PI).
18 Oct 2010 Imagine living in a world where even common germs can trigger extreme illness that won’t go away. This is the reality for nearly 10 million children and adults living with primary...
-
Oct 7, 2010Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to a Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).
07 Oct 2010 Hizentra® (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according...
-
Oct 7, 2010Privigen, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and secondary immunodeficiencies, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
07 Oct 2010 Privigen®, the first and only 10% liquid intravenous immunoglobulin (IVIg) therapy stabilized with proline, is effective and well tolerated in patients with several primary and...
-
Oct 7, 2010Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naïve patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIG) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
07 Oct 2010 Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naïve patients with primary immunodeficiency (PI) and may offer an...
-
Sep 28, 2010The American Academy of Allergy, Asthma Immunology (AAAAI) and CSL Behring are pleased to announce Duane Wesemann, MD, PhD, of Brigham and Women’s Hospital, as the recipient of the 2010 Young Investigator Award.
28 Sep 2010 The American Academy of Allergy, Asthma & Immunology (AAAAI) and CSL Behring are pleased to announce Duane Wesemann, MD, PhD, of Brigham and Women’s Hospital, as the recipient of the...
-
Sep 18, 2010CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, from 18 months to 24 months.
18 Aug 2010 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®,...
-
Sep 14, 2010CSL Behring announces the publication of its latest Key Issues Dialogue – Hereditary Angioedema (HAE) in the US. This ongoing series brings together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with rare and serious diseases.
14 Sep 2010 CSL Behring announces the publication of its latest Key Issues Dialogue – Hereditary Angioedema (HAE) in the US. This ongoing series brings together thought leaders from the medical...
-
Jun 23, 2010CSL Behring, a global leader in the plasma-protein biotherapies industry, has awarded advocacy grants totaling almost $50,000 to four patient organizations through the Local Empowerment for Advocacy Development (LEAD) program.
23 Jun 2010 CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $50,000 to four patient...
-
Jun 2, 2010CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) of moderate and severe intensity.
02 Jun 2010 CSL Behring Canada announced today that it has received Notice of Compliance for Berinert® (Human C1 Esterase Inhibitor). The company may now market Berinert for the treatment of...
-
May 27, 2010CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings to 28 the number of countries (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.
27 May 2010 CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE)...
-
May 18, 2010CSL Behring announced today the schedule for its 9th annual Gettin’ in the GameSM Junior National Championship (JNC) competition in golf and baseball. The JNC is a series of one-day athletic events for children with bleeding disorders, such as hemophilia or von Willebrand disease (VWD), and their families.
18 May 2010 CSL Behring announced today the schedule for its 9th annual Gettin’ in the GameSM Junior National Championship (JNC) competition in golf and baseball. The JNC is a series of one-day...
-
May 14, 2010Direct Relief International announced today that CSL Behring has donated life-saving medicines valued at more than $100,000 to assist earthquake victims in Haiti who are at risk of tetanus or hepatitis B infections. The products will be used in clinics at Hôpital Albert Schweitzer in Deschapelles.
14 May 2010 Direct Relief International announced today that CSL Behring has donated life-saving medicines valued at more than $100,000 to assist earthquake victims in Haiti who are at risk of...
-
May 13, 2010To promote the importance of screening young women for von Willebrand disease (VWD), the American Academy of Nurse Practitioners (AANP) today announced the launch of its VWD Young Women’s Education Campaign. Sponsored by CSL Behring, this educational initiative is designed to inform teenage girls and their healthcare providers about the five signs and symptoms of VWD, the most common hereditary bleeding disorder.
13 May 2010 To promote the importance of screening young women for von Willebrand disease (VWD), the American Academy of Nurse Practitioners (AANP) today announced the launch of its VWD Young Women’
-
Apr 19, 2010CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen®, Immune Globulin Intravenous (Human), 10% Liquid, from 24 to 36 months. The approval makes Privigen the first liquid intravenous immunoglobulin (IVIg) in the U.S. that can be stored at room temperature throughout its entire 36-month shelf life.
19 Apr 2010 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen®,...
-
Apr 16, 2010
16 Apr 2010 Hemophilia B patients in the developing world will benefit from a recent donation of 1 million international units (IU) of factor IX medication made by CSL Behring to the World...
-
Apr 12, 2010CSL Behring, a global leader in the plasma protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
12 Apr 2010 CSL Behring, a global leader in the plasma protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The...
-
Mar 4, 2010CSL Behring Receives FDA Approval of Hizentra™, First 20 Percent Subcutaneous Immunoglobulin TherapyCSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI).
04 Mar 2010 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Hizentra™, Immune Globulin Subcutaneous (Human), 20% Liquid, for...
-
Feb 26, 2010Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
26 Feb 2010 Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today...
-
Feb 26, 2010Data presented today suggest that 20 percent liquid formulation, Immune Globulin Subcutaneous (Human) (SCIg), or IgPro20 effectively protects patients with primary immunodeficiencies (PI) against infection. The 20 percent formulation, the highest Ig concentration currently available, was also shown to sustain serum IgG levels without causing unexpected rates of adverse events. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, LA, US.
26 Feb 2010 Data presented today suggest that 20 percent liquid formulation, Immune Globulin Subcutaneous (Human) (SCIg), or IgPro20 effectively protects patients with primary immunodeficiencies...
-
Feb 26, 2010Data from a European multicenter (non-IND study) showing that patients with PI who switched to IgPro20 from previously available SCIg formulations achieved comparable IgG trough levels without dosage adjustment, resulting in significantly less administration volume. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, LA, US.
26 Feb 2010 Data from a European multicenter (non-IND study) showing that patients with PI who switched to IgPro20 from previously available SCIg formulations achieved comparable IgG trough levels...
-
Feb 26, 2010Data presented today show that IgPro20, the first 20 percent liquid formulation, delivers a higher concentration of treatment, with no trade-off in terms of local tolerability relative to currently marketed subcutaneous immunoglobulin (SCIg) products. The data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in New Orleans, LA, US.
26 Feb 2010 Data presented today show that IgPro20 the first, 20 percent liquid formulation, delivers a higher concentration of treatment, with no trade-off in terms of local tolerability relative...
-
Feb 26, 2010C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
26 Feb 2010 C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients...
-
Feb 4, 2010CSL Behring announced today the start of the global clinical trial program SWIFT (Studies with von Willebrand factor [VWF]/Factor VIII) to evaluate the pharmacokinetics, efficacy and safety of Biostate®, a low-volume, highly active, plasma-derived VWF/FVIII concentrate for the treatment of von Willebrand disease (VWD) and hemophilia A.
04 Feb 2010 CSL Behring announced today the start of the global clinical trial program SWIFT (Studies with von Willebrand factor [VWF]/Factor VIII) to evaluate the pharmacokinetics, efficacy and...
-
Jan 27, 2010CSL Behring announced today the launch of the Berinert® Expert Network (B.E.N.™ ), a full-service support program for healthcare providers and for hereditary angioedema (HAE) patients and their caregivers. HAE is a rare and serious disorder that causes swelling in various parts of the body.
27 Jan 2010 CSL Behring announced today the launch of the Berinert® Expert Network (B.E.N.™ ), a full-service support program for healthcare providers and for hereditary angioedema (HAE)...
-
Dec 29, 2009CSL Behring, has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support grassroots advocacy efforts by organizations committed to helping people who use plasma-derived or recombinant therapies manage their health conditions.
29 Dec 2009 CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded four advocacy grants totaling $87,000 to patient...
-
Nov 9, 2009
09 Nov 2009 CSL Behring has begun packaging Humate-P®, (Antihemophilic Factor/von Willebrand Factor Complex [Human]) in a more user-friendly package based on customer market research. These...
-
Oct 29, 2009CSL Behring announced today the national winners of the 8th annual Gettin' in the GameSM Junior National Championship (JNC). Developed by CSL Behring, provider of the hemophilia treatment Helixate FS (Antihemophilic Factor, Recombinant), the JNC is a series of one-day events held throughout the country that provide hundreds of children with bleeding disorders the opportunity to participate in a golf and baseball competition.
29 Oct 2009 CSL Behring announced today the national winners of the 8th annual Gettin’ in the GameSM Junior National Championship (JNC). Developed by CSL Behring, provider of the hemophilia...
-
Oct 12, 2009CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients.
12 Oct 2009 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute...
-
Oct 5, 2009CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
05 Oct 2009 CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The...
-
Sep 21, 2009Helixate FS from CSL Behring Now Available in 3000 IU Dosage Strength to Improve Patient ConvenienceHemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to a new 3000 IU (international unit) dosage strength. CSL Behring announced today that this new dosage strength is available in the U.S., allowing many patients to reduce reconstitution time by eliminating the need to mix and pool multiple vials of Helixate FS.
21 Sep 2009 Hemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to...
-
Aug 17, 2009CSL Behring announced today that Helixate FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage. This new indication was granted by the FDA after determining Helixate FS is safe and effective for routine prophylaxis, which can reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A.
17 Aug 2009 CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in...
-
Jul 28, 2009CSL Behring, a global leader in the plasma-protein biotherapies industry, has awarded six advocacy grants totaling $100,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program.
28 Jul 2009 CSL Behring, a global leader in the plasma-protein biotherapies industry, has awarded six advocacy grants totaling $100,000 to patient organizations in the United States through the...
-
Jun 8, 2009CSL Limited and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which CSL agreed to acquire Talecris for US$3.1 billion in cash.
08 Jun 2009 CSL Limited (ASX: CSL) and Talecris Biotherapeutics, Inc. announced today that they have mutually agreed to terminate their merger agreement, announced on August 12, 2008, under which...
-
May 18, 2009ZLB Plasma has changed its name to CSL Plasma to align more closely with its parent company, CSL Limited. CSL Plasma is one of the world’s largest collectors of human plasma for use in manufacturing life-saving biotherapies.
18 May 2009 ZLB Plasma has changed its name to CSL Plasma to align more closely with its parent company, CSL Limited. CSL Plasma is one of the world’s largest collectors of human plasma for use...
-
May 4, 2009
04 May 2009 Hemophilia A patients and their treatment providers are now better able to manage their condition, thanks to an enhanced HeliTrax™ System from CSL Behring. Patients can now track and...
-
May 1, 2009CSL Behring announced today it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (USFDA) requesting approval to market its 20 percent liquid formulation, Immune Globulin Subcutaneous (Human) (IgSc), in the United States for weekly replacement therapy in patients with primary immunodeficiencies (PI).
01 May 2009 CSL Behring announced today it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (USFDA) requesting approval to market its 20...
-
Apr 17, 2009In recognition of the World Federation of Hemophilia’s (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating to WFH two (2) million units of factor VIII concentrate (FVIII) each year for the next three (3) years. The donation, the total value of which will be approximately $2 million, will be made using coagulation factor concentrate with a minimum shelf-life of one year.
17 Apr 2009 In recognition of the World Federation of Hemophilia's (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for...
-
Apr 2, 2009CSL Behring announced it will hold its next GameFaces™ challenge from April 14 through July 7, 2009. GameFaces is a family-oriented, online initiative for people with hemophilia A. The program is designed to encourage real-life physical activity through a series of customized challenges based on the individual’s age, disease severity and current level of physical activity.
02 Apr 2009 CSL Behring announced it will hold its next GameFaces™ challenge from April 14 through July 7, 2009. GameFaces is a family-oriented, online initiative for people with hemophilia A....
-
Mar 31, 2009CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.
31 Mar 2009 CSL Behring, a global leader in the plasma-protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development (LEAD) program. The...
-
Mar 15, 2009C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2009 American Academy of Allergy, Asthma Immunology (AAAAI) Annual Meeting. C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2009 American Academy of Allergy, Asthma Immunology (AAAAI) Annual Meeting.
15 Mar 2009 C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks at any body location in patients with hereditary...
-
Mar 15, 2009While symptoms of acute HAE attacks include episodes of edema or swelling in the hands and feet, the face, the abdomen, and/or the larynx, prodromal symptoms, which occur before an attack, are often non-specific and highly-variable, according to study findings. Treatment at the onset of these early symptoms can decrease morbidity and mortality associated with this rare and serious genetic disorder.
15 Mar 2009 The importance of recognizing prodromal symptoms and treating acute attacks of hereditary angioedema (HAE) at the onset of these symptoms was highlighted in a survey presented today at...
-
Mar 11, 2009CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven years of orphan-drug exclusivity.
11 Mar 2009 CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP™ is the first FDA-approved treatment of acute bleeding episodes in patients with...
-
Jan 16, 2009Congenital fibrinogen deficiency is a rare, potentially life-threatening bleeding disorder that affects an estimated one person per million, with an estimated prevalence in the U.S. of approximately 300 patients.
16 Jan 2009 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP™, the first and only treatment of acute bleeding episodes in...